Drug intelligence / Profile preview

dexmedetomidine + ketamine + propofol

Development stage: Preclinical
Lead developer: Orion Pharma
Modality: Small Molecules
Administration: Intravenous

Overview

This combination involves **dexmedetomidine**, a selective alpha-2 adrenergic receptor agonist with sedative, analgesic, and anxiolytic effects; **ketamine**, a non-narcotic and non-barbiturate anesthetic with analgesic properties; and **propofol**, a hypnotic agent used for sedation and anesthesia. The combination is used for procedural sedation and anesthesia, offering benefits like hemodynamic stability and reduced respiratory depression. However, specific studies on this exact combination are limited compared to combinations like ketamine-propofol or dexmedetomidine-ketamine.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)GABRR (GABA-A receptor subunit rho)ADRA2A (α2A)

Beyond the preview

Go deeper on dexmedetomidine + ketamine + propofol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexmedetomidine + ketamine + propofol.

Explore the full profile